Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination with Ibrutinib in Japanese Subjects with Relapsed/Refractory Mantle Cell Lymphoma [M20-075]

Phase 2

Completed

• Registration Number: JPRN-jRCT2080225346

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
efficacy

Secondary Outcome Measures

Name	Time	Method
safety<br>efficacy<br>pharmacokinetics<br>other